Protean Biodiagnostics
Protean BioDiagnostics offers comprehensive CAP CLIA lab services and innovative cancer diagnostic solutions, focusing on community oncology and underserved populations.
Founded
2017Protean BioDiagnostics offers comprehensive CAP CLIA lab services and innovative cancer diagnostic solutions, focusing on community oncology and underserved populations.
Protean BioDiagnostics, founded with a mission to assist cancer patients and their doctors in navigating advanced diagnostic options, offers comprehensive CAP CLIA laboratory services. The company focuses on community oncology and underserved populations, providing innovative products based on molecular analysis, genomics, bioinformatics, digital pathology, and AI. Their market focus is primarily on enhancing cancer diagnostics to ensure patients receive the most effective therapies available.
Notable figures affiliated with Protean BioDiagnostics include key researchers and industry experts in oncology diagnostics. The company has achieved significant milestones, such as the launch of Aventa FusionPlus, the first 3D genomics test for cancer patients, in collaboration with Aventa. Protean's impact lies in its commitment to improving cancer diagnosis and treatment options, particularly for underserved communities, thereby advancing the field of oncology diagnostics.
Companies similar to Protean Biodiagnostics include Complete Omics, Foundation Medicine, Neodiagnostix and Predictive Biosciences.
Protean Biodiagnostics was founded in 2017.
Protean Biodiagnostics' headquarters is located in Orlando, FL, US.
Protean Biodiagnostics' most recent funding round was for $330k (USD) in June 2019.
As of Jun 26, 2019, Protean Biodiagnostics has raised a total of $330k (USD).
Protean Biodiagnostics has 14 employees as of Feb 5, 2024.
Neodiagnostix
neodiagnostix.com
